Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 5, 2015, Pages 703-717

  Da Silva, Candido G ^a   Honeywell, Richard J ^a   Dekker, Henk ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Efflux transporters; Influx transporters; Physicochemical properties; Serine threonine kinase inhibitors; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PROTEIN KINASE INHIBITOR; CARRIER PROTEIN;

CANCER CELL; CANCER GROWTH; CANCER TISSUE; COMPUTER MODEL; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; DRUG EFFECTS; ENZYME SPECIFICITY; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; TUMOR MICROENVIRONMENT;

EID: 84928886725     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1006626     Document Type: Review

References (111)

1. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101(6):2368-73
2. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9(1):105-27
3. Saji T, Kikuchi R, Kusuhara H, et al. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. J Pharmacol Exp Ther 2008;324(2):784-90
4. Maher JM, Slitt AL, Callaghan TN, et al. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem Pharmacol 2006;72(4):512-22
5. Kikuchi R, Kusuhara H, Hattori N, et al. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1alpha/beta and DNA methylation. Mol Pharmacol 2006;70(3):887-96
6. Jin L, Kikuchi R, Saji T, et al. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. J Pharmacol Exp Ther 2012;340(3):648-55
7. Kikuchi R, Kusuhara H, Hattori N, et al. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Mol Pharmacol 2007;72(6):1619-25
8. Klein K, Jungst C, Mwinyi J, et al. The human organic anion transporter genes OAT5 and OAT7 are transactivated by hepatocyte nuclear factor-1alpha (HNF-1alpha). Mol Pharmacol 2010;78(6):1079-87
9. Popowski K, Eloranta JJ, Saborowski M, et al. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol Pharmacol 2005;67(5):1629-38
10. Wolff NA, Thies K, Kuhnke N, et al. Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. J Am Soc Nephrol 2003;14(8):1959-68
11. Zhang Q, Hong M, Duan P, et al. Organic anion transporter OAT1 undergoes constitutive and protein kinase C-regulated trafficking through a dynamin-and clathrindependent pathway. J Biol Chem 2008;283(47):32570-9
12. Takeda M, Sekine T, Endou H. Regulation by protein kinase C of organic anion transport driven by rat organic anion transporter 3 (rOAT3). Life Sci 2000;67(9):1087-93
13. Kwak JO, Kim HW, Oh KJ, et al. Co-localization and interaction of organic anion transporter 1 with caveolin-2 in rat kidney. Exp Mol Med 2005;37(3):204-12
14. Aoki K, Saso N, Kato S, et al. Nitric oxide and peroxynitrite regulate transporter transcription in rat liver slices. Biol Pharm Bull 2008;31(10):1882-7
15. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66(17):8847-57
16. Yonezawa A, Masuda S, Yokoo S, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319(2):879-86
17. Shnitsar V, Eckardt R, Gupta S, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 2009;69(4):1494-501
18. Saborowski M, Kullak-Ublick GA, Eloranta JJ. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther 2006;317(2):778-85
19. Shu Y, Bello CL, Mangravite LM, et al. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther 2001;299(1):392-8
20. Ciarimboli G, Struwe K, Arndt P, et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol 2004;201(3):420-8
21. Mehrens T, Lelleck S, Cetinkaya I, et al. The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. J Am Soc Nephrol 2000;11(7):1216-24
22. Ciarimboli G, Koepsell H, Iordanova M, et al. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 2005;16(6):1562-70
23. Cetinkaya I, Ciarimboli G, Yalcinkaya G, et al. Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am J Physiol Renal Physiol 2003;284(2):F293-302
24. Martel F, Keating E, Calhau C, et al. Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK-293 cells by intracellular second messenger systems. Naunyn Schmiedebergs Arch Pharmacol 2001;364(6):487-95
25. Schlatter E, Monnich V, Cetinkaya I, et al. The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J Membr Biol 2002;189(3):237-44
26. Oostendorp RL, van de Steeg E, van der Kruijssen CM, et al. Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 2009;37(4):917-23
27. Smith NF, Acharya MR, Desai N, et al. Identification of OATP1B3 as a highaffinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4(8):815-18
28. Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120(7):1689-99
29. Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004;101(10):3569-74
30. Katz DA, Carr R, Grimm DR, et al. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 2006;79(3):186-96
31. Miki Y, Suzuki T, Kitada K, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 2006;66(1):535-42
32. Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 2003;37(3):622-31
33. Furihata T, Satoh T, Yamamoto N, et al. Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm Res 2007;24(12):2327-32
34. Le Vee M, Lecureur V, Moreau A, et al. Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes. Drug Metab Dispos 2009;37(11):2228-35
35. Le Vee M, Jouan E, Moreau A, Fardel O. Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes. Fundam Clin Pharmacol 2011;25(1):99-103
36. Le Vee M, Gripon P, Stieger B, Fardel O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab Dispos 2008;36(2):217-22
37. Vavricka SR, Jung D, Fried M, et al. The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol 2004;40(2):212-18
38. Choi JH, Murray JW, Wolkoff AW. PDZK1 binding and serine phosphorylation regulate subcellular trafficking of organic anion transport protein 1a1. Am J Physiol Gastrointest Liver Physiol 2011;300(3):G384-93
39. Kock K, Koenen A, Giese B, et al. Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated internalization. J Biol Chem 2010;285(15):11336-47
40. Huang M, Wang Y, Cogut SB, et al. Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther 2003;304(2):753-60
41. Leisewitz AV, Zimmerman EI, Jones SZ, et al. Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine. Nucleosides Nucleotides Nucleic Acids 2008;27(6):779-86
42. Woodahl EL, Wang J, Heimfeld S, et al. Imatinib inhibition of fludarabine uptake in T-lymphocytes. Cancer Chemother Pharmacol 2008;62(4):735-9
43. Naud JS, Ghani K, de Campos-Lima PO, Caruso M. Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy. Leuk Res 2012;36(10):1311-14
44. Hu S, Niu H, Inaba H, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011;103(11):893-905
45. Damaraju VL, Kuzma M, Mowles D, et al. Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy? Mol Cancer Ther 2014. [Epub ahead of print]
46. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2(1):48-58
47. Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005;65(24):11419-28
48. Liedauer R, Svoboda M, Wlcek K, et al. Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep 2009;22(6):1485-92
49. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278(1):G156-64
50. Yamaguchi H, Okada M, Akitaya S, et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006;47(6):1196-202
51. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007;35(5):779-86
52. Muto M, Onogawa T, Suzuki T, et al. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 2007;98(10):1570-6
53. Monks NR, Liu S, Xu Y, et al. Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1-and OATP1B3-expressing HeLa cells. Mol Cancer Ther 2007;6(2):587-98
54. Nagai M, Furihata T, Matsumoto S, et al. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun 2012;418(4):818-23
55. Thakkar N, Kim K, Jang ER, et al. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm 2013;10(1):406-16
56. Lee W, Belkhiri A, Lockhart AC, et al. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008;68(24):10315-23.
57. Gotink KG, Broxterman HJ, Labots M, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011;17:7337-46
58. Kindla J, Rau TT, Jung R, et al. Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue. Cancer Biol Ther 2011;11(6):584-91
59. Wlcek K, Svoboda M, Thalhammer T, et al. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 2008;7(9):1450-5
60. Nozawa T, Suzuki M, Takahashi K, et al. Involvement of estrone-3-sulfate transporters in proliferation of hormonedependent breast cancer cells. J Pharmacol Exp Ther 2004;311(3):1032-7
61. Nozawa T, Suzuki M, Yabuuchi H, et al. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 2005;22(10):1634-41
62. Cui Y, Konig J, Nies AT, et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003;83(4):527-38
63. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44(7):793-8
64. Calcagno AM, Ludwig JA, Fostel JM, et al. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 2006;3(1):87-93
65. Gong S, Lu X, Xu Y, et al. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 2002;30(10):1162-9
66. Park T, Yi SG, Shin YK, Lee S. Combining multiple microarrays in the presence of controlling variables. Bioinformatics 2006;22(14):1682-9
67. Heise M, Lautem A, Knapstein J, et al. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012;12:109
68. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104(12):3739-45
69. Asif AR, Steffgen J, Metten M, et al. Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells. Pflugers Arch 2005;450(2):88-95
70. Holla VR, Backlund MG, Yang P, et al. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) 2008;1(2):93-9
71. Zhou F, Lee AC, Krafczyk K, et al. Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 2011;162(6):1380-8
72. Zheng J, Chan T, Cheung FS, et al. PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability. PLoS One 2014;9(4):e94712
73. Norman RA, Toader D, Ferguson AD. Structural approaches to obtain kinase selectivity. Trends Pharmacol Sci 2012;33(5):273-8
74. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26
75. Engel GL, Farid NA, Faul MM, et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000;198(2):239-47
76. le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53(4):313-23
77. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108(2):697-704
78. Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83(2):258-64
79. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14(10):3141-8
80. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15(19):6062-9
81. Eechoute K, Franke RM, Loos WJ, et al. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 2011;89(6):816-20
82. Zimmerman EI, Hu S, Roberts JL, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013;19(6):1458-66
83. Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009;15(14):4750-8
84. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011;10(3):531-9.
85. Galetti M, Alfieri RR, Cavazzoni A, et al. Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines. Biochem Pharmacol 2010;80(2):179-87
86. Elmeliegy MA, Carcaboso AM, Tagen M, et al. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res 2011;17(1):89-99
87. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008;14(12):3875-80
88. Gnoth MJ, Sandmann S, Engel K, Radtke M. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 2010;38(8):1341-6
89. de Graan AJ, Lancaster CS, Obaidat A, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012;18(16):4433-40
90. Giannoudis A, Davies A, Lucas CM, et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112(8):3348-54
91. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14(12):3881-8
92. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36(4):695-701
93. Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23(11):1999-2006
94. Brennan M, Williams JA, Chen Y, et al. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012;68(5):645-55
95. Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010;102(9):1371-7
96. Leuthold S, Hagenbuch B, Mohebbi N, et al. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 2009;296(3):C570-82
97. Di Giusto G, Anzai N, Endou H, Torres AM. Elimination of organic anions in response to an early stage of renal ischemia-reperfusion in the rat: role of basolateral plasma membrane transporters and cortical renal blood flow. Pharmacology 2008;81(2):127-36
98. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4(1):45-60
99. Marcucci F, Corti A. How to improve exposure of tumor cells to drugs: promoter drugs increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev 2012;64(1):53-68
100. Marcucci F, Corti A. Improving drug penetration to curb tumor drug resistance. Drug Discov Today 2012;17(19-20):1139-46
101. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012;165(5):1260-87
102. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70
103. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24(7):1227-51
104. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273(1):251-60
105. Johnson BM, Charman WN, Porter CJ. The impact of P-glycoprotein efflux on enterocyte residence time and enterocytebased metabolism of verapamil. J Pharm Pharmacol 2001;53(12):1611-19
106. van de Wetering K, Burkon A, Feddema W, et al. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 2009;75(4):876-85
107. Evers R, Zaman GJ, van Deemter L, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97(5):1211-18
108. Inokuchi A, Hinoshita E, Iwamoto Y, et al. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter. J Biol Chem 2001;276(50):46822-9
109. Available from: http://www. solvobiotech. com/barriers/intestinal-barrier
110. Borchardt R, Kerns E, Hageman M, et al. Optimizing the "drug-like" properties of leads in drug discovery. Springer; New Yprk: 2006
111. Honeywell RJ, Hitzerd S, Fatmawati C, et al. Uptake and subcellular distribution of tyrosine kinase inhibitors. Manuscript in preparation